Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion to an everolimus-based CNI-free regimen in kidney transplant recipients with chronic allograft nephropathy
2010-018792-17Phase 4Active
- Sponsor
- Kliniken der Stadt Köln
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus and mycophenolate sodium in Chronic Allograft Kidney Disease (CKaD) and kidney transplant, sponsored by Kliniken der Stadt Köln. Primary endpoint: Improvement of renal function by GFR slope. Started Dec 2010; status: active.
02
Drugs
everolimusmycophenolate sodium
03
Conditions
Chronic Allograft Kidney Disease (CKaD)kidney transplant
Beyond the preview
Go deeper on 2010-018792-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018792-17.